Risk of Cerebrovascular Events in 178,962 5-Year Survivors of Cancer Diagnosed Aged 15-39 Years: The Teenage and Young Adults Cancer Survivors Study (TYACSS) by Bright, CJ et al.
This is an author produced version of Risk of Cerebrovascular Events in 178,962 5-Year 
Survivors of Cancer Diagnosed Aged 15-39 Years: The Teenage and Young Adults Cancer
Survivors Study (TYACSS).
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/111821/
Article:
Bright, CJ, Hawkins, MM, Guha, J et al. (9 more authors) (2017) Risk of Cerebrovascular 
Events in 178,962 5-Year Survivors of Cancer Diagnosed Aged 15-39 Years: The Teenage 
and Young Adults Cancer Survivors Study (TYACSS). Circulation, 135 (13). pp. 1185-1187.
ISSN 0009-7322 
https://doi.org/10.1161/CIRCULATIONAHA.116.025778
(c) 2017. This is an author produced version of a paper published in Circulation. Uploaded 
in accordance with the publisher's self-archiving policy.
promoting access to
White Rose research papers
eprints@whiterose.ac.uk
http://eprints.whiterose.ac.uk/
RISK OF CEREBROVASCULAR EVENTS IN 178,962 5-YEAR SURVIVORS OF CANCER 
DIAGNOSED AGED 15-39 YEARS: THE TEENAGE AND YOUNG ADULT CANCER 
SURVIVOR STUDY (TYACSS) 
Bright, Strokes after teenage and young adult cancer 
Authors: Chloe J Bright MSc1, Mike M Hawkins DPhil1, Joyeeta Guha PhD1,2, Katherine E 
Henson DPhil3, David L Winter HNC1, Julie S Kelly1, Richard G Feltbower PhD4, Marlous 
Hall PhD4, David J Cutter DPhil3, Angela B Edgar MD5, Clare Frobisher PhD1, Raoul C 
Reulen PhD1 
1Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Science, Robert 
Aitken Building, University of Birmingham, Birmingham, UK. 
23XEOLF+HDOWK(QJODQG6W&KDG¶V&RXUWHagley Road, Birmingham, B16 9RG 
3Clinical Trial Service Unit (CTSU), Nuffield Department of Population Health, University of 
Oxford, Richard Doll Building, Old Road Campus, Oxford, UK. 
4Division of Epidemiology and Biostatistics, School of Medicine, University of Leeds, Worsley 
Building, Clarendon Way, Leeds, UK.  
5Royal Hospital for Sick Children, Edinburgh, UK. 
Corresponding author: Raoul Reulen 
Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Research, Robert 
Aitken Building, University of Birmingham, Birmingham, B15 2TT; Tel: +44(0)1214144946; 
Fax: +44(0)1214147923; Email: r.c.reulen@bham.ac.uk 
 
Manuscript length: 4,903 words, text length (incl. tables): 9,660 words 
 
1 
 
ABSTRACT 1 
Background: Survivors of teenage and young adult (TYA) cancer are at risk of 2 
cerebrovascular events, but the magnitude of and extent to which this risk varies by cancer 3 
type, decade of diagnosis, age at diagnosis and attained age remains uncertain.  This is the 4 
largest ever cohort study to evaluate the risks of hospitalisation for a cerebrovascular event 5 
among long-term survivors of TYA cancer.  6 
Methods: The population-based Teenage and Young Adult Cancer Survivor Study  7 
(N=178,962) was linked to Hospital Episode Statistics data for England to investigate the 8 
risks of hospitalisation for a cerebrovascular event among 5-year survivors of cancer 9 
diagnosed when aged 15-39 years. Observed numbers of first hospitalisations for 10 
cerebrovascular events were compared to that expected from the general population using 11 
standardised hospitalisation ratios (SHR) and absolute excess risks (AER) per 10,000 12 
person-years. Cumulative incidence was calculated with death considered a competing risk. 13 
Results: Overall, 2,782 cancer survivors were hospitalised for a cerebrovascular event²14 
40% higher than expected (SHR=1.4, 95% confidence interval [CI]=1.3-1.4). Survivors of 15 
central nervous system (CNS) tumours (SHR=4.6, CI=4.3-5.0), head & neck tumours 16 
(SHR=2.6, CI=2.2-3.1) and leukaemia (SHR=2.5, CI=1.9-3.1) were at greatest risk. Males 17 
had a significantly higher AER than females (AER=7 versus 3), especially among head & 18 
neck tumour survivors (AER=30 versus 11). By age 60, 9%, 6% and 5% of CNS tumour, 19 
head & neck tumour, and leukaemia survivors, respectively, had been hospitalised for a 20 
cerebrovascular event. Beyond age 60, every year 0.4% of CNS tumour survivors were 21 
hospitalised for a cerebral infarction (versus 0.1% expected. Whereas at any age, every year 22 
0.2% of head & neck tumour survivors were hospitalised for a cerebral infarction 7 (versus 23 
0.06% expected). 24 
Conclusions:   Survivors of a CNS tumour, head & neck tumour, and leukaemia are 25 
particularly at risk of hospitalisation for a cerebrovascular event. The excess risk of cerebral 26 
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infarction among CNS tumour survivors increases with attained age. For head & neck 1 
tumour survivors this excess risk remains high across all ages. These groups of survivors, 2 
and in particular males, should be considered for surveillance of cerebrovascular risk factors 3 
and potential pharmacological interventions for cerebral infarction prevention. 4 
 5 
Key words: teenage and young adult cancer, cerebrovascular disease, strokes 6 
  7 
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CLINICAL PERSPECTIVE 1 
x What is new? Teenage and young adult cancer survivors are widely acknowledged to 2 
be an understudied population and little is known about the risks of long-term 3 
adverse health outcomes in this group of survivors. This is the largest ever study to 4 
investigate the risk of hospitalisation for specific cerebrovascular events among 5 
survivors of all and specific types of cancer diagnosed in individuals aged 15-39 6 
years. In addition, this is the first study to investigate whether the risk of 7 
hospitalisation for a cerebrovascular event varies with attained age, age at diagnosis 8 
and decade of diagnosis. 9 
x What are the clinical implications? This study found that survivors of a CNS tumour, 10 
head & neck tumour, and leukaemia are particularly at risk of hospitalisation for a 11 
cerebrovascular event. The absolute excess risk of developing a cerebral infarction 12 
DPRQJ&16WXPRXUVXUYLYRUV¶LQFUHDVHVZLWKDWWDLQHGDJHDQGWKDWIRUKHDG	QHFN13 
tumour survivors this excess risk remained high across all ages. These groups of 14 
survivors should be considered for surveillance of cerebrovascular risk factors and 15 
potential pharmacological interventions for cerebral infarction prevention. 16 
 17 
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INTRODUCTION 
Improvements in survival over the last few decades mean that more than 80% of teenagers 
and young adults (TYA, age 15-39 years) diagnosed with cancer can expect to survive at 
least 5-years from diagnosis 1, 2. This has resulted in a large population of cancer survivors, 
who may be at increased risk of treatment related long-term adverse health effects3, 4. 
Notwithstanding this, TYA cancer survivors are an understudied population and little is 
known about the risks of long-term adverse health outcomes in this group5, 6.  
Previous studies of cancer survivors have observed an increased risk of 
cerebrovascular events after irradiation of the head, neck and mediastinum7-13. In addition to 
treatment, local recurrence and brain metastases are also potential causes of 
cerebrovascular events in cancer populations14. Development of a cerebrovascular event 
after treatment for cancer is a serious, and potentially life-threatening adverse event15, yet  
only one other large-scale population-based study has explored the risk of hospitalisation for 
a cerebrovascular event in individuals diagnosed with cancer, between the ages of 15 and 
39 years (n=43,154 1-year survivors) 16.  In this Danish study, there was a 30% increased 
risk of hospitalisation for a cerebrovascular event for all survivors combined compared to the 
general population, however, the risk varied by type of cerebrovascular event and cancer 
type. The magnitude of the effect of attained age, age at cancer diagnosis and decade of 
cancer diagnosis on the risk of specific types of cerebrovascular events (e.g. cerebral 
infarction, cerebral haemorrhage) has not previously been investigated and has often been 
encompassed within studies of all types of cardiovascular events combined9, 16, 17.  
Within the UK, the risk of having a cerebrovascular event doubles every decade after 
the age of 55 18. Currently it is unknown what the risk of cerebrovascular events is in TYA 
cancer survivors and whether this effect doubles beyond the age of 55. If this holds true for 
survivors of TYA cancer survivors this could lead to a large population of cancer survivors 
developing a cerebrovascular event in older age. 
To our knowledge, this is the largest study to investigate the risk of hospitalisation for 
specific cerebrovascular events in survivors of all and specific types of cancer diagnosed in 
5 
 
individuals aged 15-39 years. In addition, this is the first study to investigate whether the risk 
of hospitalisation for a cerebrovascular event varies with attained age, age at diagnosis and 
decade of diagnosis. 
 
METHODS 
Teenage and Young Adult Cancer Survivor Study  
The Teenage and Young Adult Cancer Survivor Study (TYACSS) is a large 
population-based cohort consisting of 200,945 5-year survivors of cancer diagnosed aged 
15-39 years between 1971 and 2006 in England and Wales. The cohort was ascertained 
from cancer registrations recorded by the Office for National Statistics and the Welsh Cancer 
Registry. Cancer registrations were coded according to the relevant revisions of the 
International Classification of Diseases (ICD) (topography) and International Classification of 
Diseases for Oncology (ICDO) (morphology). We mapped all ICD-topography and ICDO-
morphology codes into 15 main cancer types based on the classification of cancers for TYAs 
19, 20
. We refined the classification slightly to allow for inclusion of finer groupings of 
carcinomas (see Online Table 1). Ethical approval for the TYACSS was obtained from the 
National Research Ethics Service (ref: 16/LO/0895) and legal permission to process 
identifiable information without individual patient consent from the Confidentiality Advisory 
Group (ref: 3-03(c)2010). 
  
Ascertainment of Cerebrovascular Events from Hospital Episodes Statistics  
The inpatient Hospital Episode Statistics (HES) database is a national electronic 
database of routinely collected data on individual hospital admissions to National Health 
Service (NHS) and private (if care was commissioned by the NHS) hospitals in England. For 
this study HES inpatient data were available from April 1997 to December 2012. Prior to 
linking the survivor cohort by NHS number, date of birth, postcode and sex to the inpatient 
HES database, we excluded all Welsh survivors (N= 11,099 patients) due to HES being 
restricted to England only. Individuals were also excluded if they had died or emigrated 
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before the start of the follow-up period (1st April 1997) (N=10,128 patients) (see Online 
Figure 1 for flow-diagram of exclusions). It was not possible to determine the actual linkage 
rate of the survivor cohort to the inpatient HES database as not all survivors would have 
been admitted to hospital within the HES years 1997-2012. For the vast majority of survivors 
the key linkage identifiers²NHS number, date of birth, postcode and sex²were available 
and it is thus more likely that such survivors would not have been admitted to hospital rather 
than an actual failure to link the survivor to the correct HES record(s). Of the 179,718 
survivors eligible to be linked with HES, 84% (150,942) had at least one inpatient admission 
record in HES. 
 Each inpatient admission initiates a record in the HES database and contains 
information on the date of admission, methods of admission and discharge, patient 
demographics, and up to 20 diagnosis variables containing information on the primary 
condition, conditions diagnosed during hospital admission, and any pre-existing co-
morbidities. All diagnosis variables are coded using the International Classification of 
Disease version 10 (ICD-10) and are coded at the time of hospital discharge by trained 
clinical coders or clinicians using all available clinical notes21. Cerebrovascular events (ICD-
10: I60-I68) were identified from all 20 diagnosis variables recorded in HES and categorised 
into the following subgroups: subarachnoid haemorrhage (ICD-10: I60), cerebral 
haemorrhage (ICD-10: I61-I62), cerebral infarction/occlusion/stenosis (ICD-10: I63, I65-I66), 
and µother cerebrovascular event¶ (ICD-10: I64, I67-I68) (stroke not specified as 
haemorrhage or infarction (ICD-10: I64), other cerebrovascular events (ICD-10: I67), 
cerebrovascular disorders in diseases elsewhere classified (ICD-10:I68)). If an individual 
developed the same type of cerebrovascular event more than once, only the first event was 
retained for the analysis to ensure that any cerebrovascular event was not counted more 
than once due to potential duplicate recordings. Individuals who developed a 
cerebrovascular event within the first 5-years from cancer diagnosis were excluded as time 
at risk started at 5-year survival. Individuals with a first event recorded as sequelae of 
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cerebrovascular disease (ICD-10: I69), but no prior recorded cerebrovascular event in HES 
were also excluded, as such survivors would most likely have had a prior cerebrovascular 
event before April 1997. After these exclusions, a cohort of 178,962 5-year survivors 
remained (see Online Figure 1 for flow-diagram of exclusions).   
 
Statistical Analysis 
Individuals were followed-up for cerebrovascular events from 5-year survival or 1st 
April 1997, whichever date was most recent. Follow-up ended at the first occurrence of 
death, emigration, hospitalisation for a cerebrovascular event or study end date (31st 
December 2012). Cerebrovascular related hospitalisation rates for the general population 
were derived from the entire (anonymised) HES dataset for England (N=13,476,762) by 
dividing the number of individuals with a hospitalisation by the mid-year general population 
estimates 22 for each age (1-year bands), sex and calendar-year (1-year bands). The 
accumulated person-years within each corresponding age, sex and calendar year stratum in 
the survivor cohort were multiplied by the general population rates to obtain the expected 
number of cerebrovascular hospitalisations. 
Analyses were conducted to investigate the risk of a hospitalisation for all 
cerebrovascular events combined and for specific types of cerebrovascular events. The 
observed number of hospitalisations for a cerebrovascular event was divided by the number 
expected from the general population (referred to as a standardised hospitalisation ratio 
(SHR))17. The absolute excess risk (AER) is the additional number of hospitalisation for a 
cerebrovascular event compared to that expected based on general population 
hospitalisation rates, it is calculated as the observed minus the expected number of 
hospitalisation divided by the person-years at risk. The AER has been expressed per 10,000 
person-years throughout the manuscript 23. For each cerebrovascular event subtype, SHRs 
and AERs were stratified by the following factors: cancer diagnosis, sex, age at cancer 
diagnosis (15-19/20-24/25-29/30-34/35-39 years), decade of cancer diagnosis (1971-
1979/1980-1989/1990-1999/2000-2006) and attained age (20-44/45-49/50-54/55-59/
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years). To investigate the simultaneous effect of these variables on the risk of hospitalisation 
for a cerebrovascular event, multivariable Poisson regression was conducted to derive 
relative risks (RR) and excess hospitalisation ratios (EHR). RRs can be interpreted as the 
ratio of the SHRs adjusted for potential confounders. EHRs can be interpreted as the ratio of 
the AERs adjusted for potential confounders24. Negative binomial regression was preferred 
to Poisson when the data showed signs of over-dispersion (see Online Table 2 for 
dispersion parameters and regression methods used). A likelihood ratio test was used to test 
for linear trend of a factor by comparing the log-likelihood of a model including the factor 
variable of interest (e.g. attained age (20-44/45-49/50-54/55-59\HDUV, which was 
coded such that it had the median value of the variable at each level, with the log-likelihood 
of a model without the factor variable of interest. Cumulative incidence with attained age as 
the time scale was calculated treating death as a competing risk. A p-value of <0.05 (2-sided 
test) was taken as statistically significant. All statistical analyses were conducted in Stata 
statistical software (version 14.1, Stata Corp., College Station, TX).  
From here on ³hospitalisation for a cerebrovascular event´ DQG³FHUHEUDO
LQIDUFWLRQRFFOXVLRQVWHQRVLV´ZLOOEHUHIHUUHGWRDV³FHUHEURYDVFXODUHYHQW´DQG³FHUHEUDO
LQIDUFWLRQ´UHVSHFWLYHO\. 
 
RESULTS 
Cohort Characteristics 
A total of 178,962 5-year survivors of TYA cancer were included in the analysis, 
contributing 1,837,996 person-years of follow-up. Characteristics of the cohort can be found 
in Online Table 3. The median follow-up was 11.3 years (range: 0-15.8 years) with 36% of 
individuals followed for at least 15 years. In total, 2,782 (1.6%) individuals were hospitalised 
for at least one cerebrovascular event. With respect to specific types of cerebrovascular 
events; 618 (0.35% (0.18% expected)) individuals were hospitalised for a cerebral 
haemorrhage, 1,296 (0.72% (0.48% expected)) for a cerebral infarction, 262 (0.15% (0.15% 
9 
 
expected)) for a subarachnoid haemorrhage and 1,114 (0.62% (0.49% expected)) for µRWKHr 
cerebrovascular eventV¶ 
 
Risk of any cerebrovascular event 
Survivors experienced a 40% significantly increased risk of developing any 
cerebrovascular event compared to that expected from the general population (SHR=1.4, 
95% confidence interval [CI]=1.3-1.4); corresponding to four excess events per 10,000 
person-years (PY) (Table 1). Female survivors experienced significantly fewer excess 
cerebrovascular events than male survivors (AER=3 and AER=7, respectively; 
pheterogeneity<0.001). In terms of age at cancer diagnosis, SHRs for a cerebrovascular event 
were highest among individuals diagnosed with a cancer aged 15-19 years (SHR=3.6, 
CI=3.0-4.2; AER=9) and there was a significant trend for the SHR to decrease with 
increasing age at diagnosis (ptrend <0.001). The SHR declined significantly with attained age 
(ptrend<0.001), although the p-value for trend for the RR just fell short of significance when 
evaluated in the multivariable model (ptrend =0.086) (Table 2). The AERs remained elevated 
at all ages, however; the multivariable analysis showed a significant increasing trend in the 
number of excess cerebrovascular events with increasing attained age²survivors older than 
60 years had 2-fold the number of excess cerebrovascular events than survivors aged 20-44 
years (EHR=2.4, CI=1.5-4.1;ptrend<0.001) (Table 2).  
With regards to TYA cancer type, survivors at the highest risk of developing a 
cerebrovascular event were: central nervous system (CNS) tumour survivors (SHR=4.6, 
CI=4.3-5.0; AER=34); head & neck tumour survivors (SHR=2.6, CI=2.2-3.1; AER=22) and 
leukaemia survivors (SHR=2.5. CI=1.9-3.1; AER=10). The cumulative incidence of 
developing a cerebrovascular event by age 60 was 9.0%, 6.4% and 5.1% among CNS 
tumour, head & neck tumour and leukaemia survivors, respectively, whereas 2.3% was 
expected (Figure 1a). Due to having substantially increased risk, further analyses were 
conducted for CNS tumour, head & neck tumour and leukaemia survivors. 
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CNS tumour survivors 
Survivors of all CNS tumour types were at increased risk of developing a 
cerebrovascular event, particularly, survivors of embryonal tumours (SHR=12.9, CI=8.0-
19.7; AER=78) and glial tumours (SHR=10.8, CI=9.5-12.3; AER=72) (Table 3). The SHR 
was highest among survivors diagnosed when aged 15-19 years (SHR=12.7, CI=10.1-15.9); 
however survivors aged 35-39 years at diagnosis were still at 3.5-fold increased risk 
(SHR=3.5, CI=3.0-4.0). The SHR declined with increasing attained age, however remained 
elevated among all ages (ptrend<0.001). In contrast, the AER increased with attained age 
(ptrend<0.001) reaching 55 additional hospitalisations per 10,000 PY within individuals aged 
 years (Figure 2, Table 3).  
 
Head & neck tumour survivors 
Male survivors of a head & neck tumour had a significantly greater AER for a 
cerebrovascular event than female survivors (ptrend=0.002), with an excess of 30 events 
compared to 11 per 10,000 PY, respectively (Table 4).  The AER remained significantly 
increased for all ages; however the multivariable analysis showed that the AER did not 
increase significantly with attained age (ptrend=0.071) (Figure 3, Online Table 6).  
 
Leukaemia survivors 
Survivors of all types of leukaemia were at an increased risk of developing a 
cerebrovascular event and risk did not depend on type of leukaemia (pheterogeneity=0.130) 
(Table 5). Leukaemia survivors diagnosed aged 15-19 years had the greatest SHR 
(SHR=5.1, CI=2.8-8.6) and the SHR decreased significantly with older age at diagnosis 
(ptrend=0.007).  The AER increased significantly with attained age until age 55 years 
(ptrend=0.014) reaching 20 additional hospitalisations per 10,000 PY within individuals aged 
50-54 years. 
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Risk of a cerebral haemorrhage 
The SHR for a cerebral haemorrhage was twice that expected (SHR=2.0, CI=1.8-
2.1). The risk of developing a cerebral haemorrhage among survivors diagnosed more 
recently (1990-2006), was increased nearly 4-fold relative to that expected from the general 
population (SHR=3.7, CI=2.9-4.7); whereas it was only 20% increased among survivors 
diagnosed earlier (1971-1979) (SHR= 1.2, CI=1.0-1.4) (Table 1). This increase in risk for the 
recent treatment decade was further confirmed by the multivariable analysis (Ptrend=0.005) 
(Online Table 4). In terms of attained age, the SHR was highest for survivors younger than 
45 years (SHR=3.6, CI=3.1-4.2) and declined with increasing attained age, however 
remained significantly elevated for all ages (SHR at age 60+years = 1.2, CI=1.0-1.4) (Table 
2).  
With regards to TYA cancer type, the SHR was highest among survivors of a CNS 
tumour and leukaemia, with an 8-fold (SHR=8.3, CI=7.2-9.6) and 5-fold (SHR=5.2, CI=3.4-
7.6) increased risk, respectively (Table 1). The cumulative incidence of developing a 
cerebral haemorrhage by age 60 was 3.4% and 2.0% among CNS tumour and leukaemia 
survivors, respectively, whereas 0.4% was expected (Figure 1b). Notably, survivors of 
melanoma were at increased risk of developing a cerebral haemorrhage (SHR=2.0 CI=1.5-
2.6); but were not at significantly increased risk of any other cerebrovascular event. 
 
CNS tumour survivors 
The risk of developing a cerebral haemorrhage was significantly elevated among all 
CNS tumour survivors. Survivors of glial tumours were at greatest risk (SHR=26.2, CI=21.5-
31.6) (Table 3). The SHR and AER of developing a cerebral haemorrhage among CNS 
survivors diagnosed more recently (1990-2006), was 27-fold increased relative to that 
expected from the general population (SHR=26.5, CI=18.6-36.7; AER=20); whereas it was 
only 4-fold increased among survivors diagnosed earlier (1971-1979) (SHR= 4.2 , CI=2.7-
6.1; AER=10). This increase in the SHRs and AERs by more recent treatment decade was 
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confirmed by the multivariable analysis (ptrend<0.001 and 0.005, respectively) (Online Table 
5).  
 
Risk of cerebral infarction 
Overall, survivors had a 50% significantly increased risk of a cerebral infarction 
compared to that expected (SHR=1.5; CI=1.4-1.6; AER=2). In terms of age at cancer 
diagnosis, the SHR and AER for a cerebral infarction was highest among survivors 
diagnosed aged 15-19 years (SHR=4.3, CI=3.3-5.4; AER=4) (Table 1); who had twice the 
risk of a cerebral infarction than survivors diagnosed aged 35-39 years (RR=0.5, CI=0.4-0.7) 
(Online Table 4). The AER increased with increasing attained age (ptrend<0.001) (Table 2); 
after adjusting for potential confounders, survivors aged over 60 years had 6-fold the number 
of excess cerebral infarction than survivors aged less than 45 years (EHR=5.6, CI=2.9-10.8).  
With regards to TYA cancer type, the SHR was highest among survivors of CNS 
tumours (SHR=4.4, CI=3.9-5.0), head & neck tumours (SHR=3.5, CI=2.8-4.4), leukaemia 
(SHR=2.3, CI=1.5-3.3), and Hodgkin lymphoma (SHR=2.1, CI=1.8-2.5) (Table 1). The 
cumulative incidence of developing a cerebral infarction before age 60 was 4.2%, 3.6%, 
2.3% and 2.0% among head & neck tumour, CNS tumour, leukaemia and Hodgkin 
lymphoma survivors, respectively, whereas 0.9% was expected (Figure 1c). 
 
CNS tumour survivors 
The risk of developing a cerebral infarction was significantly elevated among all CNS 
tumour survivors, with the exception of µother specified¶&16WXPRXUJURXS. Survivors of 
embryonal tumours (SHR=18.8, CI=10.0-32.1) and germ cell tumours (SHR=10.5, CI=3.4-
24.6) were at greatest risk (Table 3). The AER was substantially elevated among survivors 
of embryonal tumours, with 49 excess cerebral infarctions per 10,000PY (Table 3). AERs 
increased sharply with attained age reaching 26 excess cerebral infarctions per 10,000 PY in 
survivors aged 60 years or older (ptrend<0.001) (Figure 2, Table 3). In terms of absolute risk, 
every year approximately 0.4% of CNS tumour survivors over age 60 years were 
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hospitalised for a cerebral infarction compared to approximately 0.2% in the general 
population.  
 
Head & neck tumour survivors 
Among head & neck tumour survivors, the AER for a cerebral infarction was higher 
among males than females (AER=22 and AER=7, respectively; Ptrend<0.001) (Table 4). The 
SHR decreased with attained age (ptrend<0.001), however remained elevated for all ages. 
The AER was high for all ages (AER=10-23); however did not vary significantly with attained 
age (ptrend=0.159) (Figure 3). In terms of absolute risk, every year approximately 0.2% of 
head & neck tumour survivors were hospitalised for a cerebral infarction compared to 
approximately 0.06% in the general population. 
 
Risk of subarachnoid haemorrhage  
The risk of being hospitalised for a subarachnoid haemorrhage among TYA cancer survivors 
did not differ significantly from that observed in the general population (SHR=1.0, CI=0.9-1.1; 
AER=0) (Results not shown). 
 
Risk of µother cerebrovascular events¶  
Survivors had a 40% significantly increased risk of any µother cerebrovascular events¶ 
compared to that expected (SHR=1.4, CI=1.3-1.5; AER=2) (Table 1). The SHR and AER 
was highest among survivors diagnosed aged 15-19 years (SHR=4.1, CI=3.1-5.4; AER=3) 
(Table 1); survivors diagnosed aged 15-19 years had over twice the risk of developing µRWKHU
cerebrovascular eventV¶than survivors aged 35-39 years at diagnosis (Online Table 4). The 
AER increased with increasing attained age reaching 2 per 10,000 person-years after age 
60 years, which was confirmed by the multivariable analysis, where the EHR increased 
substantially with attained age (ptrend<0.001) (Table 2).  
With regards to TYA cancer type, the risk was highest among survivors of: a CNS 
tumour (SHR=5.1, CI=4.5-5.8; AER=15), head & neck tumours (SHR=2.7, CI=2.0-3.5; 
14 
 
AER=9) and leukaemia (SHR=2.6, CI=1.7-3.8; AER=4) (Table 1). The cumulative incidence 
RIGHYHORSLQJDQµRWKHUFHUHEURYDVFXODUHYHQW¶E\DJHZDVDQGDPRQJ
CNS tumour, leukaemia and head & neck tumour survivors, respectively, whereas 0.8% was 
expected (Figure 1d). 
 
CNS tumour survivors 
Among CNS tumour survivors, tKH6+5DQG$(5IRUµRWKHUFHUHEURYDVFXODUHYHQWV¶
was highest among survivors of embryonal tumours (SHR=20.2, CI=10.4-35.3 AER=46) and 
germ cell intracranial tumours (SHR=12.6, CI=4.1-29.5; AER=23) (Table 3). AERs increased 
VXEVWDQWLDOO\ZLWKDWWDLQHGDJHUHDFKLQJH[FHVVµRWKHUFHUHEURYDVFXODUHYHQWV¶SHU 
PY in CNS tumour survivors aged 60 years or older (ptrend<0.001) (Figure 2, Table 3).  
 
Head & neck tumour survivors 
Among head & neck tumour survivors, the AER increased significantly with attained 
DJHUHDFKLQJH[FHVVµRWKHUFHUHEURYDVFXODUHYHQWV¶SHU3<LQVXUYLYRUVDJHG 
years or older (ptrend=0.002) (Figure 3, Table 4).  
 
 
DISCUSSION 
Main Findings 
In this largest ever study of TYA cancer survivors, we report a 40% increased risk of 
hospitalisation for a cerebrovascular event compared to that expected in the general 
population. TYA cancer survivors are at 2-fold, 1.5-fold and 1.4-fold increased risk of a 
cerebral haemorrhage, cerebral infarction and `other cerebrovascular event`, respectively. 
By age 60, 9%, 6% and 5% of CNS tumour, head & neck tumour, and leukaemia survivors, 
respectively, had been hospitalised for a cerebrovascular event. Male TYA cancer survivors 
had a significantly higher number of excess cerebrovascular events compared to female 
survivors, especially cerebral infarction among head and neck tumour survivors. We found 
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that the excess risk of developing a cerebral infarction among CNS tumour survivors 
increases significantly with attained age. Beyond age 60, every year approximately 0.4% of 
CNS tumour survivors can expect to be hospitalised for a cerebral infarction. The excess risk 
of developing a cerebral infarction among head & neck tumour survivors did not vary with 
attained age but was consistently high. Every year approximately 0.2% of head & neck 
tumour survivors can expect to be hospitalised for a cerebral infarction.  
 
Previous studies 
The only other large-scale cohort investigating hospitalisation for cerebrovascular 
disease²a Danish cohort study of 43,153 1-year survivors of TYA cancer (age 15-39 
years)²found a significant 1.3-fold increased risk of hospitalisation for any cerebrovascular 
disease for all survivors combined, which is comparable to the 1.4-fold increased risk 
observed in our study of 178,964 5-year survivors of TYA cancer 16. In a smaller scale study; 
van Laar et al. did not observe a significantly increased risk of cerebrovascular disease 
among 1,880 5-year survivors of TYA cancer diagnosed between 15 and 29 years in 
Yorkshire, England; however the study included only 7 cerebrovascular events compared to 
3,201 in the current study17.  
 The Danish study by Rugbjerg et al. demonstrated that CNS tumour survivors had a 
substantially increased risk of being hospitalised for a cerebrovascular event (SHR=3.9, CI: 
3.4-4.5), particularly for a cerebral haemorrhage (SHR=7.6, CI=5.7-10.2) and other 
undefined cerebrovascular disease (SHR=4.5, CI=3.6-5.5) 16; these findings are generally 
consistent with the risk estimates observed in our study.  In contrast, this study showed that 
CNS tumour survivors had a 4.4-fold (CI=3.9-5.0) increased risk of developing a cerebral 
infarction§significantly higher than the 2.9-fold (CI=2.2-3.8) risk observed by Rugbjerg et al. 
One explanation for this difference could be the more recent diagnosis period of our cohort 
(individuals diagnosed 1971-2006) compared to the Danish cohort (individuals diagnosed 
1943-2009); hence the background risk of developing a cerebral infarction in our study was 
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lower. To our knowledge, we provide for the first time, risk estimates for cerebrovascular 
disease by type of CNS tumour among TYA cancer survivors. Risk estimates for developing 
cerebrovascular disease for other tumour types, such as testicular, Hodgkin lymphoma, non-
Hodgkin lymphoma, ovary, cervical, melanoma, thyroid and leukaemia were remarkably 
similar to those found by Rugbjerg et al16.   
 
Potential Radiation-Induced Cerebrovascular Disease 
Although the mechanisms of radiation-induced cerebrovascular disease are 
unknown, cranial irradiation has been implicated in causing direct damage to endothelial 
cells of the cerebral arteries resulting in weakened vessels, accelerated atherosclerosis and 
vascular insufficiency secondary to stenosis or occlusion12, 13, 25.  Previous studies among 
childhood CNS tumour survivors have reported a strong linear dose-response relationship 
between the amount of cranial irradiation exposure and risk of developing stroke7, 8, 10, 11. 
Prophylactic cranial irradiation for childhood leukaemia has also been shown to increase the 
risk of stroke in a dose-dependent manner11. Given these observations among childhood 
cancer survivors, the substantially increased risks of cerebrovascular disease observed here 
among TYA survivors of CNS tumour and leukaemia are probably, to at least some extent, 
related to cranial irradiation as well.  Nonetheless, some cerebrovascular events²
particularly cerebral haemorrhage²may be caused by compression or damage of 
intracranial vessels from local recurrence of a CNS tumour or brain metastasis from other 
tumours (e.g. melanoma or head & neck cancer)14. This could explain the increase in 
cerebral haemorrhage among CNS tumour survivors treated most recently²a higher 
proportion of high grade glial tumours (which are likely to recur) were observed in 1990-2006 
compared to previous decades. We cannot rule out the possibility that the increase in 
cerebral haemorrhage among CNS tumour survivors diagnosed more recently may be an 
artefact of greater frequency of CNS imaging or improved diagnosis of haemorrhage in more 
recent years. Melanoma survivors were at increased risk of a cerebral haemorrhage, but not 
any other type of cerebrovascular event. Melanoma metastases are commonly 
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haemorrhagic 26 , therefore this increase could in fact be due to metastases to the brain from 
recurrent melanoma subsequent to 5-year survival. 
 
This study observed a substantially increased risk of cerebral infarction among head and 
neck tumour survivors.  Several previous studies²mainly among head and neck cancer 
patients diagnosed after age 40 years²have observed an increased risk of cerebral 
infarction after radiation to the head and neck 12, 13, 27, 28; this is likely due to radiation-induced 
damage of the carotid artery 25. The exact mechanism underlying the radiation-induced 
damage of the carotid artery remains elusive; however it may be due to direct damage to 
endothelial cells which are very radiosensitive, injury to the microvasculature network or 
accelerated atherosclerosis 25, 29-32. Radiation-induced carotid artery disease can lead to 
higher risk of cerebral infarction due to stenosis of the carotid artery itself or by embolism of 
a dislodged thrombus blocking a cerebral artery 25. However, there is the possibility that both 
head and neck cancer and cerebrovascular disease have a shared aetiology, thus smoking 
and alcohol may also be implicated in the increased risk of cerebrovascular disease. 
Nonetheless, all head and neck tumour survivors in the TYA cohort were diagnosed under 
age 40 years, and thus, exposure to smoking and alcohol is likely to play a lesser role in the 
aetiology of head and neck cancer compared to patients diagnosed after age 40 years33.  In 
addition to carotid artery irradiation, an increased risk of cerebral infarction after mediastinal 
irradiation has also been observed among a population of Hodgkin lymphoma survivors, 
likely due to cardioemboli9. This, in addition to carotid artery irradiation could explain the 2-
fold increased risk of cerebral infarction observed among Hodgkin lymphoma survivors in our 
study. 
In this study, the risk of cerebral haemorrhage was greatest among CNS tumour 
survivors diagnosed most recently (2000-2006). The increasing trend observed within this 
diagnosis period was significant for glial tumour survivors only (results not shown). Among 
survivors, the proportion of gliomas considered high grade increased from 9.5% in 1971-
1979 to 17.5% in 2000-2006. High grade tumours are more difficult to treat successfully and 
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are likely to recur and it is thus not inconceivable that, although a greater proportion of these 
individuals are becoming 5-year survivors, more aggressive treatment and/or recurrence of 
the tumour could increase the risk of cerebral haemorrhage.  
 
Recommendations for prevention of cerebrovascular disease 
To our knowledge, there are no specific guidelines for stroke prevention among 
cancer survivors. The American Heart Association/American Stroke Association (AHA/ASA) 
and Scottish Intercollegiate Guidelines Network (SIGN) guidelines recommend that 
individuals who are considered to be at high risk of stroke in the general population (e.g. 
history of coronary heart disease, previous stroke, high blood pressure, and diabetes 
mellitus) undergo regular blood pressure checks, implement lifestyle modifications (stop 
smoking and reduce alcohol consumption) and are considered for pharmacological 
intervention (e.g. antihypertensive medication and statins) to reduce the risk of stroke 34, 35. 
In this study, the absolute excess risk of cerebral infarction among CNS tumour survivors 
DQGµOther Cerebrovascular Event¶DPRQJKHDG	QHFNWXPRXUVXUYLYRUV increased with 
attained age, resulting in substantial numbers of excess cerebral infarctions DQGµOther 
Cerebrovascular Event¶ among older survivors. There is evidence suggesting that stroke risk 
is increased in cancer survivors treated with cranial irradiation in the absence of 
atherosclerotic risk factors 8, 12. As previously mentioned, cranial irradiation has been 
implicated in causing accelerated atherosclerosis, therefore it could be argued that cranial 
irradiation itself is an atherosclerotic risk factor and patients treated with cranial irradiation 
should be considered at high risk such as patients with hypertension and diabetes. It may 
therefore not be unreasonable to suggest that TYA CNS tumour and head & neck tumour 
survivors (likely treated with head & neck irradiation) should be considered for 
pharmacological interventions even in the absence of other risk factors.  A randomised 
intervention study may be required to ascertain if, and to the extent to which, these survivors 
would benefit from such treatments.  
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Study strengths and limitations 
Most previous studies used questionnaires to ascertain cerebrovascular events 
which rely on self-report and may suffer from non-response or recall bias. A strength of the 
current study²in addition to the large cohort size²was that the ascertainment of 
cerebrovascular events was entirely population-based through linkage of the TYACSS 
cohort with the population-based HES dataset, thereby eliminating potential non-response or 
recall bias. A limitation of our study is the lack of detailed treatment information, particularly 
the lack of detailed information on treatment with cranial radiotherapy (e.g. availability of 
cumulative radiation dose to the cranium). However, it would not be practically feasible to 
collect detailed information on treatment for the entire cohort of 178,962 survivors due the 
destruction of older medical notes in addition to cost and time restrictions. Nested case-
control studies would be required to investigate the risks of developing cerebrovascular 
disease in relation to elements of treatment.  
Modifiable lifestyle factors such as hypertension, diabetes, obesity and smoking may 
contribute to the elevated risk of cerebrovascular disease among cancer survivors treated 
with radiotherapy to the head, neck and mediastinum 9, 12, 27, however, we cannot confirm 
this as collecting information on lifestyle factors was beyond the scope of this study. 
We acknowledge that survivors in this cohort were treated between 1971 and 2006, 
thus the findings presented may not be translatable to individuals treated with newer 
therapies in recent years e.g. proton beam therapy. Future prospective studies would be 
needed to investigate risks of cerebrovascular events after newer treatment protocols.  
 
CONCLUSIONS 
In this large scale study investigating cerebrovascular events in teenage and young adult 
cancer survivors, we found that survivors of a CNS tumour, head & neck tumour, and 
leukaemia are particularly at risk of hospitalisation for a cerebrovascular event. The excess 
risk of developing a cerebral infarction among CNS tumour survivors increases with attained 
age.For head & neck tumour survivors this excess risk remains high across all ages. These 
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groups of survivors, and in particular males, should be considered for surveillance of 
cerebrovascular risk factors and potential pharmacological interventions for cerebral 
infarction prevention. 
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FIGURE LEGENDS 
Figure 1: Cumulative Incidence for all and specific types of cerebrovascular events, by 
attained age. Abbreviations: H&N=head and neck, CNS= central nervous system. Other = all TYA cancers 
excluding CNS, H&N and leukaemia. 
Figure 2: Absolute Excess Risk (95% CI) for any and specific types of cerebrovascular event 
(CV) according to attained age among survivors of CNS tumours. 
Figure 3: Absolute Excess Risk (95% CI) for any and specific types of cerebrovascular (CV) 
event according to attained age among survivors of head & neck tumours.  
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Table 1: Standardised Hospitalisation Ratios and Absolute Excess Risks of any cerebrovascular event, Cerebral Haemorrhage (ICD10: I61-I62), Cerebral infarction (ICD10: 
I63, I65-66), Other Cerebrovascular Event (ICD10:I64, I67-I68) by TYA cancer diagnosis, sex, age at diagnosis and decade of diagnosis. 
 
Abbreviations: CV=cerebrovascular; ICD= International classification of disease; O= observed; SHR=standardised hospitalisation ratio; AER=absolute excess risk; CI=confidence interval; FPN=first primary neoplasms; 
CNS=central nervous system; NHL=non-hodgkin lymphoma; STS=soft-tissue sarcoma; GU=genitourinary. 
*Constituting ICD10: I64-Stroke not specified as haemorrhage or infarction (n=454); I67.0 ± Dissection of cerebral arteries, non-ruptured (n=10); I67.1 ± Cerebral aneurysm, non-ruptured (n=98); I67.2 ± Cerebral 
atherosclerosis (n=38); I67.4- Hypertensive encephalopathy (n=12); I67.5-I67.8 ± Other specified cerebrovascular disease (n=399); I67.9- Cerebrovascular disease, unspecified (n=244); I68 ± Cerebrovascular disorders in 
diseases elsewhere classified (n=3).
  
Any CV Event (ICD10: I60-I68) Cerebral Haemorrhage (ICD10: I61-I62) Cerebral infarction (ICD10: I63, I65-I66) Other CV Event (ICD10: I64, I67-I68)* 
  
O SHR (95% CI) AER (95% CI) O SHR (95% CI) AER (95% CI) O SHR (95% CI) AER (95% CI) O SHR (95% CI) AER (95% CI) 
All Survivors 2782 1.4 (1.3,1.4) 4.2 (3.6,4.8) 618 2.0 (1.8,2.1) 1.6 (1.4,1.9) 1296 1.5 (1.4,1.6) 2.4 (2.0,2.7) 1114 1.4 (1.3,1.5) 1.7 (1.3,2.0) 
FPN            
Breast 288 0.8 (0.7,0.9) -2.0 (-3.1,-0.8) 48 1.0 (0.7,1.3) -0.0 (-0.5,0.4) 127 0.9 (0.8,1.1) -0.4 (-1.1,0.4) 117 0.8 (0.7,1.0) -1.0 (-1.8,-0.3) 
Testicular 278 1.0 (0.9,1.1) 0.1 (-1.3,1.4) 61 1.3 (1.0,1.7) 0.6 (-0.1,1.2) 128 1.0 (0.8,1.2) -0.1 (-1.0,0.8) 97 0.9 (0.8,1.2) -0.2 (-1.0,0.6) 
Cervix 317 1.2 (1.1,1.4) 2.4 (0.9,3.8) 47 1.2 (0.9,1.6) 0.4 (-0.2,0.9) 137 1.4 (1.1,1.6) 1.5 (0.5,2.4) 149 1.4 (1.2,1.6) 1.7 (0.7,2.7) 
Melanoma 155 0.8 (0.7,0.9) -2.0 (-3.2,-0.8) 61 2.0 (1.5,2.6) 1.5 (0.7,2.3) 47 0.6 (0.4,0.8) -1.7 (-2.4,-1.0) 47 0.6 (0.4,0.8) -1.5 (-2.1,-0.8) 
CNS tumour 616 4.6 (4.3,5.0) 33.9 (30.5,37.4) 183 8.3 (7.2,9.6) 11.2 (9.3,13.0) 256 4.4 (3.9,5.0) 13.8 (11.6,16.0) 268 5.1 (4.5,5.8) 15.1 (12.8,17.3) 
Hodgkin Lymphoma 228 1.6 (1.4,1.8) 4.8 (3.1,6.6) 43 1.7 (1.3,2.4) 1.1 (0.3,1.9) 135 2.1 (1.8,2.5) 4.2 (2.9,5.6) 76 1.4 (1.1,1.7) 1.2 (0.2,2.2) 
NHL 139 1.6 (1.4,1.9) 6.7 (3.8,9.5) 33 2.4 (1.6,3.3) 2.3 (1.0,3.7) 70 1.8 (1.4,2.3) 3.9 (1.9,6.0) 47 1.4 (1.0,1.9) 1.7 (0.1,3.4) 
Thyroid 65 0.9 (0.7,1.2) -0.6 (-2.7,1.5) 9 0.8 (0.4,1.6) -0.2 (-1.0,0.6) 34 1.2 (0.8,1.7) 0.7 (-0.8,2.3) 27 1.0 (0.6,1.4) -0.1 (-1.5,1.2) 
Gastrointestinal 88 0.9 (0.7,1.2) -1.0 (-3.9,1.9) 19 1.3 (0.8,2.1) 0.7 (-0.6,2.1) 43 1.0 (0.7,1.4) 0.1 (-2.0,2.1) 43 1.1 (0.8,1.5) 0.7 (-1.4,2.7) 
STS 84 1.3 (1.0,1.6) 3.4 (0.4,6.5) 22 2.2 (1.4,3.3) 2.0 (0.5,3.6) 42 1.5 (1.1,2.0) 2.4 (0.2,4.5) 36 1.4 (1.0,2.0) 1.8 (-0.2,3.8) 
Leukaemia 70 2.5 (1.9,3.1) 10.2 (6.2,14.2) 26 5.2 (3.4,7.6) 5.1 (2.7,7.6) 28 2.3 (1.5,3.3) 3.9 (1.3,6.4) 27 2.6 (1.7,3.8) 4.1 (1.6,6.6) 
GU (other) 93 1.6 (1.3,1.9) 8.3 (3.7,12.8) 22 2.5 (1.6,3.8) 3.2 (1.0,5.4) 46 1.8 (1.3,2.4) 4.9 (1.7,8.1) 33 1.3 (0.9,1.9) 2.0 (-0.7,4.7) 
Ovary 52 1.0 (0.7,1.3) -0.3 (-3.1,2.5) 7 0.9 (0.4,1.9) -0.1 (-1.2,0.9) 23 1.1 (0.7,1.6) 0.4 (-1.5,2.3) 20 0.9 (0.5,1.4) -0.5 (-2.2,1.2) 
Bladder 83 1.0 (0.8,1.2) -0.3 (-4.1,3.5) 10 0.8 (0.4,1.4) -0.6 (-1.9,0.7) 47 1.2 (0.9,1.6) 1.5 (-1.4,4.3) 32 0.9 (0.6,1.3) -0.6 (-2.9,1.8) 
Head & Neck 123 2.6 (2.2,3.1) 21.5 (15.4,27.7) 13 1.7 (0.9,3.0) 1.5 (-0.4,3.5) 75 3.5 (2.8,4.4) 15.0 (10.2,19.8) 51 2.7 (2.0,3.5) 8.9 (5.0,12.8) 
Other 103 1.5 (1.2,1.9) 5.8 (2.6,9.1) 14 1.3 (0.7,2.2) 0.6 (-0.6,1.7) 58 2.0 (1.5,2.5) 4.7 (2.2,7.1) 44 1.6 (1.2,2.2) 2.8 (0.6,4.9) 
P-heterogeneity  <0.001 <0.001  <0.001 <0.001  <0.001 <0.001  <0.001 <0.001 
Sex            
Male 1322 1.5 (1.5,1.6) 6.6 (5.6,7.6) 322 2.2 (2.0,2.5) 2.5 (2.0,3.0) 659 1.6 (1.5,1.7) 3.5 (2.8,4.2) 505 1.6 (1.4,1.7) 2.5 (1.9,3.2) 
Female 1460 1.3 (1.2,1.3) 2.7 (2.1,3.4) 296 1.8 (1.6,2.0) 1.1 (0.8,1.4) 637 1.4 (1.3,1.5) 1.6 (1.2,2.1) 609 1.3 (1.2,1.4) 1.1 (0.7,1.6) 
P-heterogeneity  <0.001 <0.001  0.004 <0.001  0.016 <0.001  0.001 0.006 
Age at FPN Diagnosis(years)            
15-19 148 3.6 (3.0,4.2) 8.9 (6.9,10.9) 44 5.3 (3.8,7.1) 3.0 (1.9,4.1) 67 4.3 (3.3,5.4) 4.3 (2.9,5.6) 56 4.1 (3.1,5.4) 3.5 (2.3,4.8) 
20-24 219 2.0 (1.8,2.3) 5.2 (3.9,6.6) 53 2.7 (2.0,3.5) 1.6 (0.9,2.2) 101 2.3 (1.9,2.8) 2.7 (1.8,3.7) 81 2.2 (1.7,2.7) 2.1 (1.2,2.9) 
25-29 407 1.6 (1.4,1.7) 4.2 (3.1,5.4) 91 2.1 (1.7,2.5) 1.3 (0.8,1.9) 192 1.8 (1.5,2.1) 2.4 (1.7,3.2) 164 1.7 (1.5,2.0) 2.0 (1.2,2.7) 
30-34 722 1.3 (1.2,1.4) 3.6 (2.5,4.6) 176 2.1 (1.8,2.4) 1.8 (1.3,2.3) 318 1.4 (1.2,1.5) 1.7 (1.0,2.4) 255 1.2 (1.1,1.4) 0.8 (0.2,1.5) 
35-39 1286 1.2 (1.2,1.3) 3.5 (2.4,4.6) 254 1.6 (1.4,1.8) 1.5 (1.0,2.0) 618 1.3 (1.2,1.4) 2.3 (1.6,3.1) 558 1.3 (1.2,1.4) 1.7 (1.0,2.4) 
P-trend  <0.001 <0.001  <0.001 0.079  <0.001 0.007  <0.001 0.002 
Decade of FPN Diagnosis            
1971-1979 809 1.1 (1.1,1.2) 3.9 (1.8,6.0) 118 1.2 (1.0,1.4) 0.8 (-0.0,1.6) 404 1.2 (1.1,1.4) 3.0 (1.5,4.5) 376 1.2 (1.1,1.3) 2.3 (0.8,3.7) 
1980-1989 1097 1.5 (1.4,1.6) 5.6 (4.6,6.7) 235 2.0 (1.7,2.3) 1.9 (1.4,2.3) 519 1.6 (1.5,1.8) 3.2 (2.5,4.0) 448 1.5 (1.4,1.7) 2.5 (1.8,3.2) 
1990-1999 700 1.6 (1.4,1.7) 3.4 (2.7,4.2) 195 2.5 (2.1,2.8) 1.6 (1.2,2.0) 309 1.8 (1.6,2.0) 1.8 (1.4,2.3) 239 1.5 (1.3,1.7) 1.1 (0.7,1.5) 
2000-2006 176 1.7 (1.4,1.9) 3.1 (1.9,4.2) 70 3.7 (2.9,4.7) 2.2 (1.5,3.0) 64 1.5 (1.1,1.9) 0.9 (0.2,1.6) 51 1.4 (1.0,1.8) 0.6 (0.0,1.2) 
P-trend  <0.001 <0.001  <0.001 0.089  <0.001 <0.001  0.007 <0.001 
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Table 2: Standardised Hospitalisation Ratio, Relative Risk, Absolute Excess Risk and Excess 
Hospitalisation Ratio of any and specific cerebrovascular events according to attained age. 
Cerebrovascular 
Event 
Attained 
Age (years) O SHR (95% CI) RR (95% CI)* AER (95% CI) EHR (95% CI)* 
Any CV Event 
(ICD10: I60-I68) 
20-44 549 2.0 (1.9,2.2) 1.0 Ref 3.7 (3.1,4.3) 1.0 Ref 
45-49 433 1.5 (1.3,1.6) 0.9 (0.7,1.0) 3.7 (2.6,4.7) 1.6 (1.2,2.2) 
50-54 512 1.5 (1.4,1.7) 0.9 (0.8,1.1) 6.1 (4.5,7.6) 2.1 (1.4,2.9) 
54-59 455 1.3 (1.2,1.4) 0.9 (0.7,1.0) 5.4 (3.3,7.4) 2.4 (1.5,3.6) 
 60+ 833 1.1 (1.0,1.2) 0.8 (0.7,1.0) 3.5 (0.9,6.2) 2.4 (1.5,4.1) 
 P-trend  <0.001 0.086 0.122 <0.001 
Cerebral 
Haemorrhage 
(ICD10: I61-I62) 
20-44 193 3.6 (3.1,4.2) 1.0 Ref 1.8 (1.5,2.2) 1.0 Ref 
45-49 110 2.2 (1.8,2.6) 0.7 (0.6,0.9) 1.6 (1.0,2.1) 1.1 (0.7,1.6) 
50-54 106 1.9 (1.6,2.3) 0.7 (0.5,1.0) 1.7 (1.0,2.4) 1.2 (0.7,2.0) 
54-59 92 1.7 (1.4,2.1) 0.7 (0.5,1.0) 1.9 (1.0,2.8) 1.1 (0.6,2.2) 
 60+ 117 1.2 (1.0,1.4) 0.6 (0.4,0.8) 0.7 (-0.2,1.7) 1.0 (0.4,2.3) 
 P-trend  <0.001 0.016 0.137 0.610 
Cerebral 
infarction  
(ICD10: I63, I65-
66) 
20-44 197 2.2 (1.9,2.5) 1.0 Ref 1.4 (1.0,1.8) 1.0 Ref 
45-49 191 1.8 (1.5,2.0) 0.9 (0.7,1.1) 2.2 (1.5,2.9) 2.7 (1.8,4.1) 
50-54 242 1.8 (1.6,2.0) 0.9 (0.7,1.2) 3.7 (2.7,4.8) 3.7 (2.3,6.0) 
54-59 238 1.6 (1.4,1.8) 0.8 (0.6,1.1) 4.2 (2.7,5.7) 5.1 (2.9,8.8) 
 60+ 428 1.1 (1.0,1.3) 0.7 (0.5,0.9) 2.5 (0.6,4.4) 5.6 (2.9,10.8) 
 P-trend  <0.001 0.018 <0.001 <0.001 
Other CV event 
(ICD10: I64, I67-
I68) 
20-44 161 1.8 (1.6,2.1) 1.0 Ref 1.0 (0.6,1.3) 1.0 Ref 
45-49 160 1.6 (1.3,1.8) 1.0 (0.8,1.3) 1.5 (0.8,2.2) 3.0 (1.9,4.9) 
50-54 207 1.6 (1.4,1.9) 1.1 (0.9,1.4) 2.8 (1.8,3.8) 4.4 (2.6,7.4) 
54-59 184 1.3 (1.2,1.6) 1.0 (0.7,1.3) 2.3 (1.0,3.6) 4.6 (2.5,8.7) 
60+ 402 1.1 (1.0,1.3) 0.9 (0.7,1.3) 2.3 (0.5,4.2) 6.4 (3.1,12.9) 
 
P-trend  <0.001 0.605 <0.001 <0.001 
Abbreviations: CV=cerebrovascular; ICD= International classification of disease; O= observed; SHR=standardised hospitalisation ratio; 
AER=absolute excess risk; CI=confidence interval; RR=relative risk; EHR=excess hospitalisation ratio; ref= reference level 
*Multivariable models and p-values are adjusted for cancer diagnosis, sex, age at cancer diagnosis, decade of cancer diagnosis and attained age 
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Table 3:SHRs and AERs of any cerebrovascular event, cerebral haemorrhage (ICD10: I61-I62), Cerebral infarction (ICD10:I63, I65-66) or other 
cerebrovascular event (ICD10:I64, I67-I68) among CNS tumours survivors by tumour diagnosis, sex, age at diagnosis, decade of diagnosis and attained age 
 
Abbreviations: CV=cerebrovascular; ICD= International classification of disease; O= observed; SHR=standardised hospitalisation ratio; AER=absolute excess risk; CI=confidence interval; FPN=first primary neoplasms; 
CNS=central nervous system; NHL=non-Hodgkin lymphoma; STS=soft-tissue sarcoma; GU=genitourinary. 
*Omitted from table due to few events (less than 5 observed). 
  
Any CV Event (ICD10: I60-I68) Cerebral Haemorrhage (ICD10: I61-I62) Cerebral infarction (ICD10: I63, I66-67) Other CV Event (ICD10: I64, I67-I68) 
  
O SHR (95% CI) AER (95% CI) O SHR (95% CI) AER (95% CI) O SHR (95% CI) AER (95% CI) O SHR (95% CI) AER (95% CI) 
All CNS tumours 616 4.6 (4.3,5.0) 33.9 (30.5,37.4) 183 8.3 (7.2,9.6) 11.2 (9.3,13.0) 256 4.4 (3.9,5.0) 13.8 (11.6,16.0) 268 5.1 (4.5,5.8) 15.1 (12.8,17.3) 
CNS tumour type             
Glial Tumour 254 10.8 (9.5,12.3) 72.3 (62.5,82.1) 108 26.2 (21.5,31.6) 32.1 (25.8,38.3) 94 9.3 (7.5,11.4) 25.9 (20.1,31.8) 89 10.1 (8.1,12.4) 24.8 (19.1,30.5) 
Embryonal Tumour 21 12.9 (8.0,19.7) 78.0 (41.9,114.2) * * * 13 18.8 (10.0,32.1) 49.1 (20.9,77.3) 12 20.2 (10.4,35.3) 45.6 (18.5,72.7) 
Craniopharyngioma 24 6.0 (3.8,8.9) 43.9 (22.8,65.0) 5 7.3 (2.4,17.0) 9.3 (-0.2,18.7) 12 6.8 (3.5,11.9) 22.1 (7.5,36.8) 10 6.5 (3.1,12.0) 18.5 (5.0,32.0) 
Other Pituitary Tumours 115 3.4 (2.8,4.0) 21.7 (16.1,27.4) 12 2.1 (1.1,3.7) 1.7 (-0.1,3.5) 55 3.8 (2.8,4.9) 10.8 (6.9,14.7) 61 4.6 (3.5,5.9) 12.8 (8.7,16.9) 
Meningioma 52 2.1 (1.5,2.7) 12.9 (6.1,19.6) 13 3.4 (1.8,5.7) 4.3 (1.0,7.7) 24 2.2 (1.4,3.3) 6.2 (1.7,10.8) 20 1.9 (1.2,3.0) 4.6 (0.4,8.7) 
Ependymoma 30 4.9 (3.3,7.0) 35.5 (19.5,51.5) 6 5.7 (2.1,12.4) 7.3 (0.2,14.3) 17 6.1 (3.6,9.8) 21.0 (9.1,32.9) 13 5.5 (3.0,9.5) 15.7 (5.3,26.2) 
Germ Cell Intracranial 9 8.1 (3.7,15.3) 40.5 (10.3,70.8) * * * 5 10.5 (3.4,24.6) 23.1 (0.7,45.5) 5 12.6 (4.1,29.5) 23.4 (1.1,45.7) 
Other specified 56 2.0 (1.5,2.6) 10.3 (4.8,15.7) 22 4.8 (3.0,7.3) 6.5 (3.1,9.9) 19 1.5 (0.9,2.4) 2.4 (-0.8,5.6) 26 2.3 (1.5,3.4) 5.5 (1.8,9.2) 
Other Unspecified 55 5.9 (4.4,7.7) 47.2 (32.2,62.2) 14 9.0 (4.9,15.0) 12.6 (5.2,20.1) 17 4.1 (2.4,6.5) 13.0 (4.8,21.2) 32 8.7 (5.9,12.2) 28.9 (17.6,40.3) 
P-heterogeneity  <0.001 <0.001  <0.001 <0.001  <0.001 <0.001  <0.001 <0.001 
Sex            
Male 339 4.8 (4.3,5.3) 40.8 (35.3,46.3) 105 8.5 (6.9,10.2) 13.9 (10.9,16.9) 140 4.2 (3.5,4.9) 16.0 (12.5,19.5) 153 5.8 (4.9,6.8) 19.1 (15.4,22.7) 
Female 277 4.4 (3.9,4.9) 28.0 (23.8,32.3) 78 8.1 (6.4,10.2) 8.9 (6.6,11.1) 116 4.8 (3.9,5.7) 11.9 (9.2,14.7) 115 4.4 (3.7,5.3) 11.6 (8.9,14.3) 
P-heterogeneity  0.272 <0.001  0.805 0.006  0.280 0.066  0.028 0.001 
Age at FPN Diagnosis (years)            
15-19 79 12.7 (10.1,15.9) 37.7 (28.7,46.8) 28 21.8 (14.5,31.5) 13.7 (8.4,19.0) 32 13.6 (9.3,19.2) 15.2 (9.5,20.9) 30 14.8 (10.0,21.1) 14.4 (8.9,19.9) 
20-24 67 6.3 (4.9,8.0) 25.5 (18.3,32.8) 17 8.5 (5.0,13.7) 6.7 (3.1,10.4) 28 6.7 (4.4,9.6) 10.7 (6.1,15.4) 28 7.5 (5.0,10.9) 10.9 (6.3,15.6) 
25-29 113 5.7 (4.7,6.8) 33.1 (25.7,40.5) 34 9.7 (6.7,13.6) 10.7 (6.7,14.8) 48 5.8 (4.3,7.7) 14.0 (9.2,18.8) 49 6.7 (5.0,8.9) 14.7 (9.9,19.5) 
30-34 146 4.1 (3.4,4.8) 32.5 (25.5,39.5) 53 9.1 (6.8,11.9) 13.8 (9.6,17.9) 52 3.3 (2.5,4.4) 10.7 (6.5,14.8) 56 4.0 (3.1,5.2) 12.3 (8.1,16.6) 
35-39 211 3.5 (3.0,4.0) 38.7 (31.3,46.0) 51 5.4 (4.0,7.1) 10.5 (7.0,14.1) 96 3.5 (2.8,4.2) 17.4 (12.5,22.3) 105 4.1 (3.4,5.0) 20.3 (15.2,25.4) 
P-trend  <0.001 0.393  <0.001 0.791  <0.001 0.555  <0.001 0.111 
Decade of FPN Diagnosis            
1971-1979 142 3.3 (2.8,3.9) 53.4 (40.9,66.0) 26 4.2 (2.7,6.1) 10.4 (5.1,15.6) 59 3.0 (2.3,3.8) 20.6 (12.6,28.5) 83 4.5 (3.6,5.5) 34.2 (24.7,43.7) 
1980-1989 234 4.6 (4.1,5.3) 38.5 (32.2,44.8) 49 5.8 (4.3,7.7) 8.4 (5.6,11.2) 107 4.9 (4.0,5.9) 17.7 (13.5,21.9) 115 5.9 (4.9,7.1) 19.8 (15.5,24.2) 
1990-1999 179 5.4 (4.6,6.2) 24.8 (20.3,29.2) 72 11.9 (9.3,15.0) 11.1 (8.3,13.9) 71 5.4 (4.2,6.8) 9.8 (7.0,12.6) 57 4.9 (3.7,6.3) 7.7 (5.2,10.2) 
2000-2006 61 8.5 (6.5,10.9) 31.5 (22.5,40.5) 36 26.5 (18.6,36.7) 20.3 (13.4,27.1) 19 6.3 (3.8,9.9) 9.3 (4.4,14.3) 13 5.4 (2.9,9.2) 6.2 (2.1,10.3) 
P-trend  <0.001 <0.001  <0.001 0.005  <0.001 <0.001  0.451 <0.001 
Attained Age (years)       
      
20-44 200 8.4 (7.3,9.7) 24.6 (20.7,28.5) 87 17.9 (14.4,22.1) 11.4 (8.9,14.0) 65 8.2 (6.3,10.4) 7.9 (5.7,10.1) 50 6.6 (4.9,8.7) 5.9 (4.0,7.8) 
44-49 118 5.5 (4.6,6.6) 36.0 (28.1,43.9) 40 10.5 (7.5,14.4) 13.4 (8.8,17.9) 52 6.4 (4.8,8.5) 16.2 (11.0,21.5) 54 7.2 (5.4,9.5) 17.2 (11.9,22.5) 
50-54 104 4.4 (3.6,5.4) 41.8 (31.4,52.1) 24 6.1 (3.9,9.1) 10.2 (5.3,15.1) 40 4.1 (2.9,5.5) 15.5 (9.1,21.8) 58 6.6 (5.0,8.5) 25.2 (17.6,32.9) 
54-59 88 3.9 (3.1,4.8) 51.3 (36.8,65.7) 15 4.2 (2.4,7.0) 8.8 (3.0,14.6) 46 4.4 (3.2,5.9) 27.5 (17.2,37.8) 44 4.9 (3.6,6.6) 27.1 (17.1,37.2) 
60+ 106 2.5 (2.1,3.0) 54.6 (37.3,71.9) 17 2.9 (1.7,4.6) 9.1 (2.5,15.8) 53 2.4 (1.8,3.2) 26.0 (14.1,37.9) 62 3.2 (2.4,4.1) 35.7 (22.7,48.6) 
P-trend  <0.001 <0.001  <0.001 0.441  <0.001 <0.001  <0.001 <0.001 
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Table 4: SHRs and AERs of any cerebrovascular event, Cerebral infarction (ICD10: I63, I65-66) or Other Cerebrovascular Event (ICD10: I67-I68) among 
survivors of head and neck tumours by sex, age at diagnosis, decade of diagnosis and attained age 
 
Any CV Event (ICD10: I60-I68) Cerebral infarction (ICD10: I63, I65-66) Other CV Event (ICD10: I64, I67-I68) 
  
O SHR (95%CI) AER (95%CI) O SHR (95%CI) AER (95%CI) O SHR (95%CI) AER (95%CI) 
All HN tumours 123 2.6 (2.2,3.1) 21.5 (15.4,27.7) 75 3.5 (2.8,4.4) 15.0 (10.2,19.8) 51 2.7 (2.0,3.5) 8.9 (5.0,12.8) 
Sex 
         
Male 91 2.9 (2.3,3.6) 30.4 (20.9,39.9) 58 3.8 (2.9,4.9) 21.5 (14.0,29.0) 36 2.9 (2.0,4.0) 11.7 (5.8,17.5) 
Female 32 2.1 (1.4,2.9) 10.5 (3.5,17.6) 17 2.8 (1.6,4.4) 6.9 (1.8,12.0) 15 2.3 (1.3,3.8) 5.4 (0.6,10.2) 
p-heterogeneity 
 
0.098 0.002  0.258 0.001  0.494 0.027 
Age at FPN Diagnosis (years) 
         
15-24 12 4.6 (2.4,8.0) 16.0 (4.4,27.6) 8 7.8 (3.3,15.3) 11.9 (2.4,21.3) * * * 
25-29 14 2.6 (1.4,4.3) 13.5 (1.9,25.2) 8 3.3 (1.4,6.5) 8.8 (0.1,17.5) 8 3.9 (1.7,7.6) 9.4 (0.6,18.1) 
30-34 31 2.5 (1.7,3.6) 20.4 (8.6,32.3) 18 3.2 (1.9,5.1) 13.5 (4.5,22.4) 13 2.7 (1.4,4.5) 8.7 (1.1,16.3) 
35-39 66 2.5 (1.9,3.2) 28.1 (16.8,39.4) 41 3.3 (2.4,4.5) 20.1 (11.3,28.9) 27 2.4 (1.6,3.5) 11.0 (3.9,18.1) 
p-trend 
 
0.152 0.053  0.116 0.106  0.288 0.096 
Decade of FPN Diagnosis 
         
1971-1979 35 1.8 (1.3,2.5) 25.5 (6.8,44.2) 19 2.0 (1.2,3.2) 15.2 (1.7,28.8) 19 2.2 (1.3,3.4) 16.1 (2.7,29.6) 
1980-1989 40 2.5 (1.8,3.4) 21.0 (10.1,31.9) 25 3.4 (2.2,5.1) 15.5 (6.9,24.0) 18 2.8 (1.7,4.5) 10.1 (2.9,17.3) 
1990-2006 48 4.2 (3.1,5.6) 20.5 (12.9,28.1) 31 6.5 (4.4,9.2) 14.6 (8.5,20.7) 14 3.5 (1.9,5.9) 5.6 (1.5,9.7) 
p-trend  <0.001 0.799 
 <0.001 0.991  0.158 0.119 
Attained Age (years)    
   
   
20-44 23 4.6 (2.9,6.8) 13.2 (6.3,20.1) 15 8.6 (4.8,14.2) 9.7 (4.2,15.3) 6 3.7 (1.4,8.1) 3.2 (-0.3,6.7) 
44-49 22 3.8 (2.4,5.7) 22.6 (9.7,35.4) 14 6.2 (3.4,10.4) 16.3 (6.1,26.5) 7 3.4 (1.4,7.1) 6.9 (-0.3,14.0) 
50-54 23 3.2 (2.1,4.9) 28.6 (11.7,45.5) 16 5.4 (3.1,8.7) 23.3 (9.3,37.3) 8 3.0 (1.3,6.0) 9.5 (-0.3,19.4) 
54-59 18 2.3 (1.3,3.6) 24.5 (4.3,44.7) 10 2.7 (1.3,5.0) 15.3 (0.4,30.2) 7 2.3 (0.9,4.7) 9.3 (-3.0,21.7) 
60+ 37 1.8 (1.3,2.5) 32.7 (8.8,56.5) 20 1.8 (1.1,2.9) 17.9 (0.8,35.0) 23 2.4 (1.5,3.6) 25.7 (7.5,43.9) 
p-trend  <0.001 0.029  <0.001 0.159  0.215 0.002 
Abbreviations: CV=cerebrovascular; ICD= International classification of disease; O= observed; SHR=standardised hospitalisation ratio; AER=absolute excess risk; CI=confidence interval; FPN=first primary neoplasms; 
CNS=central nervous system; NHL=non-Hodgkin lymphoma; STS=soft-tissue sarcoma; GU=genitourinary. 
*Omitted from table due to few events (less than 5 observed). 
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Table 5: SHR, AER, RR and EHR of any cerebrovascular event among survivors of leukaemia by , 
type of leukaemia, sex, age at diagnosis, decade of diagnosis and attained age. 
  
O SHR (95%CI) RR (95%CI) AER (95%CI) EHR (95%CI) 
All Leukaemia 70 2.5 (1.9,3.1) 
 
10.2 (6.2,14.2) 
 
Type of Leukaemia 
     
Acute Lymphoblastic 18 3.7 (2.2,5.9) 1.0 Ref 12.4 (4.6,20.3) 1.0 Ref 
Acute Myeloid 16 1.7 (1.0,2.8) 0.6 (0.3,1.1) 4.5 (-0.8,9.7) 0.3 (0.1,1.7) 
Chronic Myeloid 13 2.9 (1.6,5.0) 0.9 (0.4,2.0) 12.3 (2.1,22.5) 1.1 (0.3,3.8) 
Other 23 2.3 (1.5,3.5) 0.9 (0.4,1.9) 15.9 (4.5,27.3) 1.0 (0.3,3.5) 
p-heterogeneity 
 
0.13 0.297 0.15 0.322 
Sex 
     
Male 47 2.7 (2.0,3.6) 1.0 Ref 13.0 (7.1,18.9) 1.0 Ref 
Female 23 2.1 (1.3,3.1) 0.8 (0.5,1.4) 6.6 (1.4,11.9) 0.5 (0.2,1.3) 
p-heterogeneity 
 
0.29 0.409 0.262 0.258 
Age at FPN Diagnosis (years) 
     
15-19 14 5.1 (2.8,8.6) 1.0 Ref 12.0 (4.2,19.9) 1.0 Ref 
20-24 6 2.2 (0.8,4.7) 0.4 (0.2,1.1) 4.7 (-2.3,11.8) 0.4 (0.1,1.8) 
25-29 10 2.4 (1.2,4.4) 0.4 (0.2,1.0) 8.1 (-0.5,16.8) 0.4 (0.1,1.8) 
30-34 22 3.0 (1.9,4.5) 0.5 (0.2,1.2) 17.4 (6.4,28.4) 0.6 (0.1,2.7) 
35-39 18 1.6 (0.9,2.5) 0.2 (0.1,0.7) 7.3 (-2.0,16.6) 0.2 (0.0,1.3) 
p-trend 
 
0.007 0.017 0.696 0.15 
Decade of FPN Diagnosis 
     
1971-1979 13 2.3 (1.2,3.9) 1.0 Ref 21.7 (0.5,42.9) 1.0 Ref 
1980-1989 23 2.3 (1.4,3.4) 1.2 (0.5,2.9) 11.0 (3.0,19.0) 1.0 (0.2,4.5) 
1990-2006 34 2.7 (1.9,3.7) 1.7 (0.6,4.7) 8.3 (3.9,12.8) 1.1 (0.2,5.9) 
p-trend 
 
0.527 0.162 0.116 0.775 
Attained Age (years) 
     
20-44 22 2.7 (1.7,4.2) 1.0 Ref 5.5 (1.9,9.1) 1.0 Ref 
44-49 19 3.1 (1.9,4.9) 1.6 (0.8,3.3) 17.5 (5.9,29.1) 5.0 (1.3,18.9) 
50-54 14 2.6 (1.4,4.4) 1.6 (0.7,3.5) 20.4 (3.1,37.8) 6.0 (1.2,30.8) 
55+ 15 1.6 (0.9,2.7) 1.3 (0.5,3.6) 16.3 (-4.7,37.4) 7.9 (1.1,55.7) 
p-trend 
 
0.142 0.429 0.014 0.01 
 
Abbreviations: O= observed; SHR=standardised hospitalisation ratio; AER=absolute excess risk; CI=confidence interval; RR=relative risk; 
EHR=excess hospitalisation ratio.
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Figure 2 
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Figure 3 
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